The genetics of Parkinson’s disease: review of current and emerging candidates

References

• Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223–236; discussion 222.
   PubMed Web of Science ®Google Scholar
• Tretiakoff C. Contributions a l’etude de l’anatomie pathologique du locus niger de soemmering avec quelques deductions relatives a la pathogenie des troubles de tonus musculaire et de la maladie de Parkinson [A study of the pathological anatomy of the locus niger of Soemerring and its relevance to the pathogenesis of changes in muscular tone in Parkinson’s disease]. Paris: 1919. French.
   Google Scholar
• PD Gene (database on Internet). PDGENE - Field synopsis of genetic assocation studies in PD. Available from: http://www.pdgene.org/. Accessed June 3, 2014.
   Google Scholar
• Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science. 1996;274(5290):1197–1199.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–2047.
   PubMed Web of Science ®Google Scholar
• Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306–318.
   PubMed Web of Science ®Google Scholar
• Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov Disord. 2013;28(6):811–813.
   PubMed Web of Science ®Google Scholar
• Bellani S, Sousa VL, Ronzitti G, Valtorta F, Meldolesi J, Chieregatti E. The regulation of synaptic function by alpha-synuclein. Commun Integr Biol. 2010;3(2):106–109.
   PubMedGoogle Scholar
• Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–840.
   PubMed Web of Science ®Google Scholar
• Miller DW, Hague SM, Clarimon J, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology. 2004;62(10):1835–1838.
   PubMed Web of Science ®Google Scholar
• Mueller JC, Fuchs J, Hofer A, et al. Multiple regions of alpha-synuclein are associated with Parkinson’s disease. Ann Neurol. 2005;57(4):535–541.
   PubMed Web of Science ®Google Scholar
• Pals P, Lincoln S, Manning J, et al. Alpha-Synuclein promoter confers susceptibility to Parkinson’s disease. Ann Neurol. 2004;56(4):591–595.
   PubMed Web of Science ®Google Scholar
• Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s disease. PLoS Genet. 2011;7(6):e1002141.
   PubMed Web of Science ®Google Scholar
• Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74(2):97–109.
   PubMedGoogle Scholar
• Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet. 2010;42(9):781–785.
   PubMed Web of Science ®Google Scholar
• Nalls MA, Plagnol V, Hernandez DG, et al; International Parkinson Disease Genomics Consortium. Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377(9766):641–649.
   PubMed Web of Science ®Google Scholar
• Pankratz N, Beecham GW, DeStefano AL, et al; PD GWAS Consortium. Meta-analysis of Parkinson’s disease: identification of a novel locus, RIT2. Ann Neurol. 2012;71(3):370–384.
   PubMed Web of Science ®Google Scholar
• Saad M, Lesage S, Saint-Pierre A, et al; French Parkinson’s Disease Genetics Study Group. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson’s disease in the European population. Hum Mol Genet. 2011;20(3):615–627.
   PubMed Web of Science ®Google Scholar
• Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet. 2009;41(12):1303–1307.
   PubMed Web of Science ®Google Scholar
• Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009;41(12):1308–1312.
   PubMed Web of Science ®Google Scholar
• Simón-Sánchez J, van Hilten JJ, van de Warrenburg B, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet. 2011;19(6):655–661.
   PubMed Web of Science ®Google Scholar
• Spencer CC, Plagnol V, Strange A, et al; UK Parkinson’s Disease Consortium; Wellcome Trust Case Control Consortium 2. Dissection of the genetics of Parkinson’s disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet. 2011;20(2):345–353.
   PubMed Web of Science ®Google Scholar
• Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44(4):595–600.
   PubMed Web of Science ®Google Scholar
• Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601–607.
   PubMed Web of Science ®Google Scholar
• Healy DG, Falchi M, O’Sullivan SS, et al. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7(7):583–590.
   PubMed Web of Science ®Google Scholar
• Carmine Belin A, Westerlund M, Sydow O, et al. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord. 2006;21(10):1731–1734.
   PubMed Web of Science ®Google Scholar
• Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol. 2006;59(4):714–719.
   PubMed Web of Science ®Google Scholar
• Wu X, Tang KF, Li Y, et al. Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord. 2012;18(6):722–730.
   PubMed Web of Science ®Google Scholar
• Kett LR, Dauer WT. Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harb Perspect Med. 2012;2(3):a009407.
   PubMed Web of Science ®Google Scholar
• MacLeod DA, Rhinn H, Kuwahara T, et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s disease risk. Neuron. 2013;77(3):425–439.
   PubMed Web of Science ®Google Scholar
• Qing H, Zhang Y, Deng Y, McGeer EG, McGeer PL. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem Biophys Res Commun. 2009;390(4):1229–1234.
   PubMed Web of Science ®Google Scholar
• Qing H, Wong W, McGeer EG, McGeer PL. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun. 2009;387(1):149–152.
   PubMed Web of Science ®Google Scholar
• Ohta E, Kawakami F, Kubo M, Obata F. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson’s disease-associated mutations. FEBS Lett. 2011;585(14):2165–2170.
   PubMed Web of Science ®Google Scholar
• Kawakami F, Yabata T, Ohta E, et al. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One. 2012;7(1):e30834.
   PubMed Web of Science ®Google Scholar
• Balicki D, Beutler E. Gaucher disease. Medicine (Baltimore). 1995; 74(6):305–323.
   PubMed Web of Science ®Google Scholar
• Lwin A, Orvisky E, Goker-Alpan O, Lamarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab. 2004;81(1):70–73.
   PubMed Web of Science ®Google Scholar
• Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37–52.
   PubMed Web of Science ®Google Scholar
• Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82(3):192–207.
   PubMed Web of Science ®Google Scholar
• Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology. 2007;69(12):1270–1277.
   PubMed Web of Science ®Google Scholar
• Cullen V, Sardi SP, Ng J, et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol. 2011;69(6):940–953.
   PubMed Web of Science ®Google Scholar
• Vilarino-Guell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89(1):162–167.
   PubMed Web of Science ®Google Scholar
• Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011;89(1):168–175.
   PubMed Web of Science ®Google Scholar
• Bonifacino JS, Hurley JH. Retromer. Curr Opin Cell Biol. 2008;20(4):427–436.
   PubMed Web of Science ®Google Scholar
• Wider C, Skipper L, Solida A, et al. Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat Disord. 2008;14(6):465–470.
   PubMed Web of Science ®Google Scholar
• Kumar KR, Weissbach A, Heldmann M, et al. Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch Neurol. 2012;69(10):1360–1364.
   PubMedGoogle Scholar
• Sharma M, Ioannidis JP, Aasly JO, et al. GEOPD consortium. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet. 2012;49(11):721–726.
   PubMed Web of Science ®Google Scholar
• Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011;89(3):398–406.
   PubMed Web of Science ®Google Scholar
• Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31(14):3038–3062.
   PubMed Web of Science ®Google Scholar
• Lesage S, Condroyer C, Klebe S, et al; French Parkinson’s Disease Genetics Study Group. EIF4G1 in familial Parkinson’s disease: pathogenic mutations or rare benign variants? Neurobiol Aging. 2012;33(9):2233.e1–2233.e5.
   Google Scholar
• Li K, Tang BS, Guo JF, et al. Analysis of EIF4G1 in ethnic Chinese. BMC Neurol. 2013;13:38.
   PubMed Web of Science ®Google Scholar
• Tucci A, Charlesworth G, Sheerin UM, Plagnol V, Wood NW, Hardy J. Study of the genetic variability in a Parkinson’s Disease gene: EIF4G1. Neurosci Lett. 2012;518(1):19–22.
   PubMed Web of Science ®Google Scholar
• Schulte EC, Mollenhauer B, Zimprich A, et al. Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson’s disease. Neurogenetics. 2012;13(3):281–285.
   PubMed Web of Science ®Google Scholar
• Edvardson S, Cinnamon Y, Ta-Shma A, et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One. 2012;7(5):e36458.
   PubMed Web of Science ®Google Scholar
• Köroğlu Ç, Baysal L, Cetinkaya M, Karasoy H, Tolun A. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord. 2013;19(3):320–324.
   PubMed Web of Science ®Google Scholar
• Vilariño-Güell C, Rajput A, Milnerwood AJ, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet. 2014;23(7):1794–1801.
   PubMed Web of Science ®Google Scholar
• Ungewickell E, Ungewickell H, Holstein SE, et al. Role of auxilin in uncoating clathrin-coated vesicles. Nature. 1995;378(6557):632–635.
   PubMed Web of Science ®Google Scholar
• Paspalas CD, Rakic P, Goldman-Rakic PS. Internalization of D2 dopamine receptors is clathrin-dependent and select to dendro-axonic appositions in primate prefrontal cortex. Eur J Neurosci. 2006;24(5):1395–1403.
   PubMed Web of Science ®Google Scholar
• Foo JN, Liany H, Tan LC, et al. DNAJ mutations are rare in Chinese Parkinson’s disease patients and controls. Neurobiol Aging. 2014;35(4):935.e1–935.e2.
   PubMed Web of Science ®Google Scholar
• Jesús S, Gómez-Garre P, Carrillo F et al. Analysis of c.801-2A>G mutation in the DNAJC6 gene in Parkinson’s disease in southern Spain. Parkinsonism Relat Disord. 2014;20(2):248–249.
   PubMed Web of Science ®Google Scholar
• Follett J, Norwood SJ, Hamilton NA, et al. The Vps35 D620N mutation linked to Parkinson’s disease disrupts the cargo sorting function of retromer. Traffic. 2014;15(2):230–244.
   PubMed Web of Science ®Google Scholar
• Cullen V, Lindfors M, Ng J, et al. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain. 2009;2:5.
   PubMed Web of Science ®Google Scholar
• Compta Y, Parkkinen L, O’Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain. 2011;134(Pt 5):1493–1505.
   PubMedGoogle Scholar
• Horvath J, Herrmann FR, Burkhard PR, Bouras C, Kövari E. Neuropathology of dementia in a large cohort of patients with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(10):864–868; discussion 864.
   PubMed Web of Science ®Google Scholar
• Goedert M, Crowther RA, Spillantini MG. Tau mutations cause frontotemporal dementias. Neuron. 1998;21(5):955–958.
   PubMed Web of Science ®Google Scholar
• Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene. Hum Mol Genet. 1999;8(4):711–715.
   PubMed Web of Science ®Google Scholar
• Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau. Ann Neurol. 1997;41(2):277–281.
   PubMed Web of Science ®Google Scholar
• Pastor P, Ezquerra M, Muñoz E, et al. Significant association between the tau gene A0/A0. Ann Neurol. 2000;47(2):242–245.
   PubMed Web of Science ®Google Scholar
• Wray S, Lewis PA. A tangled web – tau and sporadic Parkinson’s disease. Front Psychiatry. 2010;1:150.
   PubMedGoogle Scholar
• Carmine A, Buervenich S, Sydow O, Anvret M, Olson L. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson’s disease. Mov Disord. 2002;17(4):764–766.
   PubMed Web of Science ®Google Scholar
• Belin AC, Ran C, Anvret A, et al. Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson’s disease. Neurosci Lett. 2012;522(1):30–35.
   PubMed Web of Science ®Google Scholar
• Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 2001;11(1):77–84.
   PubMedGoogle Scholar
• Bolden A, Noy GP, Weissbach A. DNA polymerase of mitochondria is a gamma-polymerase. J Biol Chem. 1977;252(10):3351–3356.
   PubMed Web of Science ®Google Scholar
• Anvret A, Westerlund M, Sydow O, et al. Variations of the CAG trinucleotide repeat in DNA polymerase γ (POLG1) is associated with Parkinson’s disease in Sweden. Neurosci Lett. 2010;485(2):117–120.
   PubMed Web of Science ®Google Scholar
• Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci. 2008;1147:93–104.
   PubMed Web of Science ®Google Scholar
• Xiromerisiou G, Hadjigeorgiou GM, Papadimitriou A, Katsarogiannis E, Gourbali V, Singleton AB. Association between AKT1 gene and Parkinson’s disease: a protective haplotype. Neurosci Lett. 2008;436(2):232–234.
   PubMed Web of Science ®Google Scholar
• Ran C, Westerlund M, Anvret A, et al. Genetic studies of the protein kinase AKT1 in Parkinson’s disease. Neurosci Lett. 2011;501(1):41–44.
   PubMed Web of Science ®Google Scholar
• Malagelada C, Jin ZH, Greene LA. RTP801 is induced in Parkinson’s disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci. 2008;28(53):14363–14371.
   PubMed Web of Science ®Google Scholar
• Timmons S, Coakley MF, Moloney AM, O’ Neill C. Akt signal transduction dysfunction in Parkinson’s disease. Neurosci Lett. 2009;467(1):30–35.
   PubMed Web of Science ®Google Scholar
• Lill CM, Roehr JT, McQueen MB, et al; 23andMe Genetic Epidemiology of Parkinson’s Disease Consortium; International Parkinson’s Disease Genomics Consortium; Parkinson’s Disease GWAS Consortium; Wellcome Trust Case Control Consortium 2). Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet. 2012;8(3):e1002548.
   PubMed Web of Science ®Google Scholar
• Ekwa-Ekoka C, Diaz GA, Carlson C, et al. Genomic organization and sequence variation of the human integrin subunit alpha8 gene (ITGA8). Matrix Biol. 2004;23(7):487–496.
   PubMed Web of Science ®Google Scholar
• Müller U, Wang D, Denda S, Meneses JJ, Pedersen RA, Reichardt LF. Integrin alpha8beta1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis. Cell. 1997;88(5):603–613.
   PubMed Web of Science ®Google Scholar
• Schnapp LM, Breuss JM, Ramos DM, Sheppard D, Pytela R. Sequence and tissue distribution of the human integrin alpha 8 subunit: a beta 1-associated alpha subunit expressed in smooth muscle cells. J Cell Sci. 1995;108 (Pt 2):537–544.
   PubMedGoogle Scholar
• Chan CS, Chen H, Bradley A, Dragatsis I, Rosenmund C, Davis RL. α8-integrins are required for hippocampal long-term potentiation but not for hippocampal-dependent learning. Genes Brain Behav. 2010;9(4):402–410.
   PubMed Web of Science ®Google Scholar
• Fung HC, Scholz S, Matarin M, et al. Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006;5(11):911–916.
   PubMed Web of Science ®Google Scholar
• Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet. 2005;77(5):685–693.
   PubMed Web of Science ®Google Scholar
• Pankratz N, Wilk JB, Latourelle JC, et al; PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124(6):593–605.
   PubMedGoogle Scholar
• International Parkinson’s Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identifies several new loci for Parkinson’s disease. PLoS Genet. 2011;7(6):e1002142.
   PubMed Web of Science ®Google Scholar
• Rhodes SL, Sinsheimer JS, Bordelon Y, Bronstein JM, Ritz B. Replication of GWAS associations for GAK and MAPT in Parkinson’s disease. Ann Hum Genet. 2011;75(2):195–200.
   PubMedGoogle Scholar
• Chen YP, Song W, Huang R, et al. GAK rs1564282 and DGKQ rs11248060 increase the risk for Parkinson’s disease in a Chinese population. J Clin Neurosci. 2013;20(6):880–883.
   PubMed Web of Science ®Google Scholar
• Kimura SH, Tsuruga H, Yabuta N, Endo Y, Nojima H. Structure, expression, and chromosomal localization of human GAK. Genomics. 1997;44(2):179–187.
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Greene LE. Multiple roles of auxilin and hsc70 in clathrin-mediated endocytosis. Traffic. 2007;8(6):640–646.
   PubMed Web of Science ®Google Scholar
• Dumitriu A, Pacheco CD, Wilk JB, et al. Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson’s disease: results from the GenePD Study. Hum Mol Genet. 2011;20(8):1478–1487.
   PubMed Web of Science ®Google Scholar
• Grünblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm. 2004;111(12):1543–1573.
   PubMed Web of Science ®Google Scholar
• Mérida I, Avila-Flores A, Merino E. Diacylglycerol kinases: at the hub of cell signalling. Biochem J. 2008;409(1):1–18.
   PubMedGoogle Scholar
• Tucci A, Nalls MA, Houlden H, et al. Genetic variability at the PARK16 locus. Eur J Hum Genet. 2010;18(12):1356–1359.
   PubMed Web of Science ®Google Scholar
• Yan Y, Tian J, Mo X, et al. Genetic variants in the RAB7L1 and SLC41A1 genes of the PARK16 locus in Chinese Parkinson’s disease patients. Int J Neurosci. 2011;121(11):632–636.
   PubMed Web of Science ®Google Scholar
• Tan EK, Kwok HH, Kwok HK, et al. Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. Neurology. 2010;75(6):508–512.
   PubMed Web of Science ®Google Scholar
• Ramirez A, Ziegler A, Winkler S, et al. Association of Parkinson disease to PARK16 in a Chilean sample. Parkinsonism Relat Disord. 2011;17(1):70–71.
   PubMed Web of Science ®Google Scholar
• Vilariño-Güell C, Ross OA, Aasly JO, et al. An independent replication of PARK16 in Asian samples. Neurology. 2010;75(24):2248–2249.
   PubMed Web of Science ®Google Scholar
• Mata IF, Yearout D, Alvarez V, et al. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson’s disease. Mov Disord. 2011;26(5):819–823.
   PubMed Web of Science ®Google Scholar
• Pihlstrøm L, Axelsson G, Bjørnarå KA, et al. Supportive evidence for 11 loci from genome-wide association studies in Parkinson’s disease. Neurobiol Aging. 2013;34(6):1708.e7–1708.e13.
   PubMed Web of Science ®Google Scholar
• Goytain A, Quamme GA. Functional characterization of human SLC41A1, a Mg2+ transporter with similarity to prokaryotic MgtE Mg2+ transporters. Physiol Genomics. 2005;21(3):337–342.
   PubMed Web of Science ®Google Scholar
• Kolisek M, Nestler A, Vormann J, Schweigel-Röntgen M. Human gene SLC41A1 encodes for the Na+/Mg²+ exchanger. Am J Physiol Cell Physiol. 2012;302(1):C318–C326.
   PubMed Web of Science ®Google Scholar
• Fleig A, Schweigel-Röntgen M, Kolisek M. Solute Carrier Family SLC41, what do we really know about it? Wiley Interdiscip Rev Membr Transp Signal. 2013;2(6):227–239.
   Google Scholar
• Shimizu F, Katagiri T, Suzuki M, et al. Cloning and chromosome assignment to 1q32 of a human cDNA (RAB7L1) encoding a small GTP-binding protein, a member of the RAS superfamily. Cytogenet Cell Genet. 1997;77(3–4):261–263.
   PubMedGoogle Scholar
• Spanò S, Liu X, Galán JE. Proteolytic targeting of Rab29 by an effector protein distinguishes the intracellular compartments of human-adapted and broad-host Salmonella. Proc Natl Acad Sci U S A. 2011;108(45):18418–18423.
   PubMed Web of Science ®Google Scholar
• Grundt K, Haga IV, Aleporou-Marinou V, Drosos Y, Wanvik B, Østvold AC. Characterisation of the NUCKS gene on human chromosome 1q32.1 and the presence of a homologous gene in different species. Biochem Biophys Res Commun. 2004;323(3):796–801.
   PubMed Web of Science ®Google Scholar
• Ostvold AC, Norum JH, Mathiesen S, Wanvik B, Sefland I, Grundt K. Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. Eur J Biochem. 2001;268(8):2430–2440.
   PubMedGoogle Scholar
• Miyake Y, Tanaka K, Fukushima W, et al; Fukuoka Kinki Parkinson’s Disease Study Group. Lack of association between BST1 polymorphisms and sporadic Parkinson’s disease in a Japanese population. J Neurol Sci. 2012;323(1–2):162–166.
   PubMed Web of Science ®Google Scholar
• Zhu LH, Luo XG, Zhou YS, et al. Lack of association between three single nucleotide polymorphisms in the PARK9, PARK15, and BST1 genes and Parkinson’s disease in the northern Han Chinese population. Chin Med J (Engl). 2012;125(4):588–599.
   PubMed Web of Science ®Google Scholar
• Liu J, Xiao Q, Wang Y, et al. Analysis of genome-wide association study-linked loci in Parkinson’s disease of Mainland China. Mov Disord. 2013;28(13):1892–1895.
   PubMed Web of Science ®Google Scholar
• Sharma M, Ioannidis JP, Aasly JO, et al; GEO-PD Consortium. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012;79(7):659–667.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Kimura N, Sato K, et al. ADP ribosyl cyclase activity of a novel bone marrow stromal cell surface molecule, BST-1. FEBS Lett. 1994;356(2–3):244–248.
   PubMed Web of Science ®Google Scholar
• Kaisho T, Ishikawa J, Oritani K, et al. BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth. Proc Natl Acad Sci U S A. 1994;91(12):5325–5329.
   PubMed Web of Science ®Google Scholar
• Ortolan E, Vacca P, Capobianco A, et al. CD157, the Janus of CD38 but with a unique personality. Cell Biochem Funct. 2002;20(4):309–322.
   PubMed Web of Science ®Google Scholar
• Lampe JB, Gossrau G, Herting B, et al. HLA typing and Parkinson’s disease. Eur Neurol. 2003;50(2):64–68.
   PubMed Web of Science ®Google Scholar
• Ahmed I, Tamouza R, Delord M, et al. Association between Parkinson’s disease and the HLA-DRB1 locus. Mov Disord. 2012;27(9):1104–1110.
   PubMed Web of Science ®Google Scholar
• Saiki M, Baker A, Williams-Gray CH, et al. Association of the human leucocyte antigen region with susceptibility to Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81(8):890–891.
   PubMed Web of Science ®Google Scholar
• Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, Payami H. Evidence for more than one Parkinson’s disease-associated variant within the HLA region. PLoS One. 2011;6(11):e27109.
   PubMed Web of Science ®Google Scholar
• Botta-Orfila T, Sànchez-Pla A, Fernández M, Carmona F, Ezquerra M, Tolosa E. Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson’s disease. Brain Res. 2012;1466:152–157.
   PubMed Web of Science ®Google Scholar
• Lin CH, Chen ML, Yu CY, Wu RM. RIT2 variant is not associated with Parkinson’s disease in a Taiwanese population. Neurobiol Aging. 2013;34(9):2236.e1–2236.e3.
   Web of Science ®Google Scholar
• Lee CH, Della NG, Chew CE, Zack DJ. Rin, a neuron-specific and calmodulin-binding small G-protein, and Rit define a novel subfamily of ras proteins. J Neurosci. 1996;16(21):6784–6794.
   PubMed Web of Science ®Google Scholar
• Navaroli DM, Stevens ZH, Uzelac Z, et al. The plasma membrane-associated GTPase Rin interacts with the dopamine transporter and is required for protein kinase C-regulated dopamine transporter trafficking. J Neurosci. 2011;31(39):13758–13770.
   PubMed Web of Science ®Google Scholar
• von Poser C, Ichtchenko K, Shao X, Rizo J, Südhof TC. The evolutionary pressure to inactivate. A subclass of synaptotagmins with an amino acid substitution that abolishes Ca2+ binding. J Biol Chem. 1997;272(22):14314–14319.
   PubMed Web of Science ®Google Scholar
• Ibata K, Hashikawa T, Tsuboi T, et al. Non-polarized distribution of synaptotagmin IV in neurons: evidence that synaptotagmin IV is not a synaptic vesicle protein. Neurosci Res. 2002;43(4):401–406.
   PubMed Web of Science ®Google Scholar
• Ferguson GD, Anagnostaras SG, Silva AJ, Herschman HR. Deficits in memory and motor performance in synaptotagmin IV mutant mice. Proc Natl Acad Sci U S A. 2000;97(10):5598–5603.
   PubMed Web of Science ®Google Scholar